Koninklijke Philips N.V. $PHG Shares Acquired by Russell Investments Group Ltd.

Russell Investments Group Ltd. grew its holdings in Koninklijke Philips N.V. (NYSE:PHG - Free Report) by 7.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 482,753 shares of the technology company's stock after purchasing an additional 31,535 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.05% of Koninklijke Philips worth $12,262,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of PHG. Colonial Trust Co SC raised its holdings in shares of Koninklijke Philips by 724.0% in the 4th quarter. Colonial Trust Co SC now owns 1,409 shares of the technology company's stock valued at $36,000 after purchasing an additional 1,238 shares in the last quarter. Bessemer Group Inc. grew its position in shares of Koninklijke Philips by 2,935.4% in the 1st quarter. Bessemer Group Inc. now owns 1,973 shares of the technology company's stock worth $51,000 after buying an additional 1,908 shares during the last quarter. Castlekeep Investment Advisors LLC purchased a new position in shares of Koninklijke Philips in the 4th quarter worth approximately $114,000. Allworth Financial LP grew its position in shares of Koninklijke Philips by 16.2% in the 1st quarter. Allworth Financial LP now owns 4,638 shares of the technology company's stock worth $115,000 after buying an additional 645 shares during the last quarter. Finally, Wealthquest Corp purchased a new position in shares of Koninklijke Philips in the 1st quarter worth approximately $116,000. Institutional investors own 13.67% of the company's stock.

Analyst Ratings Changes

Separately, Wall Street Zen downgraded shares of Koninklijke Philips from a "buy" rating to a "hold" rating in a research report on Saturday, August 2nd. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Buy".

Koninklijke Philips Stock Performance

PHG traded down $0.3150 on Thursday, reaching $27.4450. 340,307 shares of the stock were exchanged, compared to its average volume of 994,296. The company's 50-day moving average price is $25.03 and its 200 day moving average price is $25.01. Koninklijke Philips N.V. has a fifty-two week low of $21.48 and a fifty-two week high of $32.91. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.26 and a quick ratio of 0.81. The firm has a market capitalization of $26.43 billion, a PE ratio of 144.50, a PEG ratio of 0.75 and a beta of 0.75.

Koninklijke Philips (NYSE:PHG - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The technology company reported $0.41 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.12. Koninklijke Philips had a return on equity of 11.95% and a net margin of 1.00%.The company had revenue of $5.05 billion during the quarter, compared to analysts' expectations of $4.35 billion. As a group, sell-side analysts forecast that Koninklijke Philips N.V. will post 1.63 EPS for the current fiscal year.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.